Displaying drugs 826 - 850 of 2785 in total
| Name | Weight | Structure | Description | Categories |
|---|---|---|---|---|
| Oseltamivir | 312.4045 C16H28N2O4 |  | A neuraminidase inhibitor used in the prophylaxis and treatment of influenza. | Acetamides / Antiviral Agents / Neuraminidase Inhibitors |
| Palmitic Acid | 256.4241 C16H32O2 |  | A fatty used as a food additive and emollient or surfactant in cosmetics. | Enzyme Inhibitors / Palmitic Acids |
| Cetyl alcohol | 242.4406 C16H34O |  | No therapeutic indications in medicinal products. Indicated to be used as an indirect additive in food contact substances, or an ingredient in commercial or cosmetic products. | Alcohols / Drugs that are Mainly Renally Excreted / Lipids |
| Decamethonium | 258.4863 C16H38N2 |  | For use as a skeletal muscle relaxant | Neuromuscular Depolarizing Agents |
| Pramlintide | 3949.44 C171H267N51O53S2 |  | An amylin analog used for the management of type 1 and type 2 diabetes mellitus as an adjunct to preprandial insulin therapy in patients without adequate glycemic control of insulin therapy. | Amylin Analog |
| Zilucoplan | 3562.229 C172H278N24O55 |  | A complement inhibitor used to treat generalized myasthenia gravis in anti-acetylcholine receptor (AChR) antibody-positive adults. | Amino Acids, Peptides, and Proteins / Antineoplastic and Immunomodulating Agents / Blood Proteins / Complement Inactivating Agents / Immunoproteins / Immunosuppressive Agents / Peptides / Proteins |
| Doravirine | 425.749 C17H11ClF3N5O3 |  | A non-nucleoside reverse transcriptase inhibitor used in combination with other antiretrovirals to treat HIV-1 infections. | Non-Nucleoside Reverse Transcriptase Inhibitors |
| Quazepam | 386.794 C17H11ClF4N2S |  | A long-acting benzodiazepine used to manage insomnia. | Benzodiazepines and benzodiazepine derivatives |
| Selinexor | 443.313 C17H11F6N7O |  | Selinexor is indicated in combination with bortezomib and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Selinexor is also indicated... | Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Nuclear Export Inhibitors / OATP1B3 inhibitors |
| Letrozole | 285.3027 C17H11N5 |  | An aromatase inhibitor used to treat breast cancer in postmenopausal women. | Antineoplastic Agents / Aromatase Inhibitors / Nitriles / Triazoles |
| Tovorafenib | 506.29 C17H12Cl2F3N7O2S |  | A type II RAF inhibitor used to treat pediatric low-grade glioma with BRAF gene mutations. | B-Raf serine-threonine kinase (BRAF) inhibitors / BCRP/ABCG2 Inhibitors / Cytochrome P-450 CYP1A2 Inducers / Cytochrome P-450 CYP1A2 Inducers (strength unknown) / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Sulfur Compounds |
| Triazolam | 343.21 C17H12Cl2N4 |  | A benzodiazepine used for short term treatment of insomnia. | Adjuvants, Anesthesia / Anti-Anxiety Agents / Benzodiazepines and benzodiazepine derivatives / GABA Modulators |
| Resmetirom | 435.22 C17H12Cl2N6O4 |  | A thyroid hormone receptor-beta agonist used to treat noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis in adults. | BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / BSEP/ABCB11 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (weak) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / OAT3/SLC22A8 Inhibitors / OATP1B1/SLCO1B1 Inhibitors / OATP1B1/SLCO1B1 Substrates / OATP1B3 inhibitors / OATP1B3 substrates / Pyrimidines / Pyrimidinones / Thyroid hormone receptor-beta (THR-beta) agonist / UGT1A4 Inhibitors / UGT1A9 Inhibitors |
| Halazepam | 352.738 C17H12ClF3N2O |  | Used to relieve anxiety, nervousness, and tension associated with anxiety disorders. | Benzodiazepines and benzodiazepine derivatives |
| Belzutifan | 383.34 C17H12F3NO4S |  | An inhibitor of hypoxia-inducible factor 2α used as an antineoplastic in the treatment of certain cancers associated with von Hippel-Lindau (VHL) disease. | Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Hypoxia-inducible Factor Inhibitor / MATE 2 Inhibitors / MATE inhibitors / OATP1B1/SLCO1B1 Substrates / OATP1B3 substrates / P-glycoprotein substrates / UGT2B17 substrates |
| Benziodarone | 518.089 C17H12I2O3 |  | Benziodarone is a uricostatic and a uricosuric agent which is sold also under the name Amplivex-Labaz. It is used in the treatment of gout . It was withdrawn from France... | Uricosuric Agents |
| Alprazolam | 308.765 C17H13ClN4 |  | A triazolobenzodiazepine with intermediate onset commonly used to treat panic disorders and generalized anxiety in addition to anxiety associated with depression. | Anti-Anxiety Agents |
| Phthalylsulfathiazole | 403.43 C17H13N3O5S2 |  | A sulfonamide antibacterial indicated in the treatment of gastrointestinal infections. | Sulfonamides |
| Lesinurad | 404.28 C17H14BrN3O2S |  | A uric acid 1 transporter inhibitor typically used in combination with a xanthine oxidase inhibitor to treat hyperuricemia associated with gout in patients with inadequate control of uric acid levels with xanthine oxidase inhibitor monotherapy. | Preparations Increasing Uric Acid Excretion |
| Roflumilast | 403.207 C17H14Cl2F2N2O3 |  | A selective phosphodiesterase-4 inhibitor indicated to decrease the risk of exacerbations in patients with severe chronic obstructive pulmonary disease (COPD) and to treat plaque psoriasis. | Phosphodiesterase 4 Inhibitors |
| Celecoxib | 381.372 C17H14F3N3O2S |  | An NSAID used to treat osteoarthritis, rheumatoid arthritis, acute pain, menstrual symptoms, and to reduce polyps is familial adenomatous polyposis. | COX-2 Inhibitors / Sulfonamides |
| Rosoxacin | 294.3047 C17H14N2O3 |  | For the treatment of bacterial infection of respiratory tract, urinary tract, GI, CNS and immuno compromised patients. | Anti-Infective Agents |
| Rofecoxib | 314.356 C17H14O4S |  | A COX-2 inhibitor NSAID used to treat osteoarthritis, rheumatoid arthritis, acute pain, primary dysmenorrhea, and migraine attacks. | COX-2 Inhibitors / Selective Cyclooxygenase 2 Inhibitors (NSAIDs) |
| Selumetinib | 457.68 C17H15BrClFN4O3 |  | A MEK 1/2 inhibitor used in pediatric patients to treat neurofibromatosis type 1 (NF1) accompanied by symptomatic, inoperable plexiform neurofibromas (PN). | Mitogen-activated protein kinase (MEK) inhibitors |
| Binimetinib | 441.233 C17H15BrF2N4O3 |  | A medication used to treat metastatic melanoma with specific mutations. | Mitogen-activated protein kinase (MEK) inhibitors / Protein Kinase Inhibitors |
Displaying drugs 826 - 850 of 2785 in total